Supply issue: Candesartan cilexetil tablets (all strengths; 4mg, 8mg,16mg and 32mg)

We are writing to update you on a supply issue affecting candesartan.  Due to issues at the manufacturing plant, there is extremely limited supply of all strengths (4 mg, 8 mg, 16 mg, and 32 mg) of Candesartan tablets (Candestar brand and all alternative brands).

To help manage available stock and maintain access, from 1 July 2026 monthly dispensing will apply to all strengths of candesartan to support equitable distribution while supply remains constrained.

Alternative brands are listed (funded) from 1 July 2026 to support continuity of supply:

• A Medsafe‑approved alternative, Candesartan Viatris Sante 4mg tablet, has been sourced, and is being repackaged.

• Candesartan Viatris (8 mg, 16 mg, 32 mg) have been listed as an alternative, with a Medsafe labelling exemption, and can be prescribed and dispensed as Medsafe approved medicines.

• Additional brands that are not Medsafe approved (APO‑Candesartan, Sandoz‑Candesartan, Candesartan Mylan) must be prescribed and supplied in line with Section 29A of the Medicines Act.

Please note:

• Patients may need to temporarily switch brands, with support from prescribers and pharmacists.

• At this stage, the funded brand Candestar is expected to return in September 2026.

• For further details please refer to the Candesartan notice on the Pharmac website.

  
  

Questions: 

If you have any queries, please contact us at enquiry@pharmac.govt.nz.

Please share this information:

Please share this information with your colleagues and within your networks.

Ngā mihiDr David Hughes

David Hughes

Chief Medical Officer | Director Advice & Assessment